Clinical trial
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected…
NCT00203892 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00203892 |
|---|---|
| Title | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma |
| Official title | A Randomized Pilot Phase II Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas |
| Lead sponsor | University of Chicago, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Adenocarcinoma |
| Intervention type | Biological |
| Interventions | modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg) |
| Enrollment | 23 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2009 |
| Completion | May 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: